To Evaluate the Efficacy, Safety, Tolerability and Pharmacokinetic Profile of ABN401 in Patients With Advanced Solid Tumors Harboring c-MET Dysregulation
NCT ID: NCT05541822
Last Updated: 2025-05-22
Study Results
Results pending
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
Recruitment Status
RECRUITING
Clinical Phase
PHASE2
Total Enrollment
178 participants
Study Classification
INTERVENTIONAL
Study Start Date
2023-01-17
Study Completion Date
2029-02-28
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
ABN401-003 is a Phase 2 clinical study to assess efficacy, safety, tolerability and pharmacokinetic profile of ABN401 (vabametkib) in specific populations of advance solid tumors with c-MET alterations as monotherapy.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
To Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Antitumor Activity of ABN401 in Patients With Advanced Solid Tumors and Non-Small Cell Lung Cancer Harboring c-MET Dysregulation
NCT04052971
Advanced Solid Tumors
COMPLETED
PHASE1
A Study of the Safety, Tolerability and Pharmacokinetics of ABBV-368 as a Single Agent and Combination in Subjects With Locally Advanced or Metastatic Solid Tumors
NCT03071757
Advanced Solid Tumors Cancer
COMPLETED
PHASE1
AMT-253 in Patients With Selected Advanced Solid Tumours
NCT05906862
Advanced Solid Tumor
RECRUITING
PHASE1
Subjects With Advanced or Metastatic Solid Tumor Malignancies
NCT05474859
Metastatic Solid Tumor
Advanced Solid Tumor
NOT_YET_RECRUITING
PHASE1
A Phase I Study to Assess the Safety and Distribution of VB-111 in Patients With Advanced Metastatic Cancer
NCT00559117
Advanced and/or Metastatic Solid Organ Cancer
UNKNOWN
PHASE1
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
This study will start with one cohort and it will be a parallel cohort expansion study.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Advanced Solid Tumors
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
Allocation Method
RANDOMIZED
Intervention Model
PARALLEL
Primary Study Purpose
TREATMENT
Blinding Strategy
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Cohort 1: Vabametkib
Subjects will receive vabametkib 800 mg, monotherapy, administered orally once daily in 21-day cycles
Group Type
EXPERIMENTAL
Vabametkib
Intervention Type
DRUG
Tablets
Route of Administration: Oral
Cohort 2: Lazertinib & Vabametkib
Part 1 (Safety Run-in): Subjects will receive lazertinib 240 mg in combination with one of three assigned dose levels of vabametkib, administered orally once daily in 21-day cycles
Part 2 (Random Dose Optimization): A maximum of two vabametkib dose levels will be evaluated in this part. Patients will be randomized in 1:1 ratio to vabametkib dose level 1 (selected from Part 1) plus the determined dose of lazertinib or dose level 2 (selected from Part 1) plus the determined dose of lazertinib
Part 3 (Randomized Clinical Trial): Patients will be randomized in 1:1 ratio to optimized vabametkib dose (selected from Part 2) plus lazertinib or Standard of Care (SOC) arm. SOC arm will be decided by the time of Part 3 initiation
Group Type
EXPERIMENTAL
Vabametkib
Intervention Type
DRUG
Tablets
Route of Administration: Oral
Lazertinib
Intervention Type
DRUG
Tablets
Route of Administration: Oral
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Vabametkib
Tablets
Route of Administration: Oral
Intervention Type
DRUG
Lazertinib
Tablets
Route of Administration: Oral
Intervention Type
DRUG
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
1. Male or female ≥ 18 years of age or designated age of majority according to the regulatory authorities, whichever is higher.
2. Eastern Cooperative Oncology Group (ECOG) performance status (PS), 0 or 1.
3. Have a life expectancy of at least 3 months.
4. Diagnosis:
1. must have histologically or cytologically confirmed NSCLC, advanced, recurrent, or metastatic,
2. For Cohort 1: MET exon 14 skipping suspected by local or central biomarker assessment. \[local testing is accepted for eligibility; all patients will have confirmation by central laboratory, but this result is not necessary for eligibility; local molecular pathology result will suffice\]. This testing can be from archival or fresh tissue sample and/or blood specimen; any sample, any test positive subjects are eligible.
3. For Cohort 2:
* Non-squamous histology (confirmed by histology or cytology)
* EGFR mutation-positive including exon 19 deletions or exon 21 L858R as detected by an FDA-approved or other validated test in a CLIA certified laboratory (sites in the US) or an accredited local laboratory (sites outside of the US) in accordance with site standard of care. (Note: A copy of the test report documenting the EGFR mutation must be included in the participant records and it must be reviewed by the Medical monitor.)
* Radiological documentation of disease progression while on continuous treatment with the 1st line 3rd generation EGFR-TKI
* Prior objective clinical benefit defined by either partial or complete radiological response, or durable SD (SD should last \> 6 months) from the 1st line 3rd generation EGFR-TKI
* Interval between documentation of radiological progression of disease on the 1st line 3rd generation EGFR TKI and first dose of study drug should be ≤ 60 days
* MET amplification or overexpression from tumor sample collected following progression on 1st line 3rd generation EGFR-TKI • Amplification GCN ≥ 10 indicated by FISH (confirmed centrally, slides or image from local laboratory will be confirmed by the central pathologist) or NGS (confirmed either centrally or locally) • Overexpression indicated by IHC90+ (i.e. 3+ staining in ≥ 90% tumor cells by central test, if local IHC results are available, image from local laboratory will be confirmed by central pathologist. Despite the image submission, tissue unstained slides should be sent to central laboratory for confirmation of MET amplification or overexpression.)
5. Treatment experience
1. Cohort 1: Anti-tumor treatment naïve subject upon refusal to receive 1st line standard of care, or not tolerated to 1st line standard of care, or progressed after standard of care with no greater than 2 prior treatment regimens (neoadjuvant, adjuvant, and maintenance therapies do not qualify as separate treatment regimens).
2. Cohort 2: Progressed on prior the 1st line 3rd generation EGFR-TKI for the treatment of advanced/metastatic NSCLC
6. At least one measurable lesion per response evaluation criteria in solid tumors (RECIST) 1.1
7. While on study treatment and for 6 months after the last dose of study treatment, a patient must:
1. Not breast feed or be pregnant.
2. Not donate gametes (ie, eggs or sperm) or freeze for future use for the purpose of assisted reproduction.
3. Wear an external condom when engaging in any activity that allows for passage of ejaculate to another person.
4. If of childbearing potential
i. Have a negative highly sensitive (eg, beta-human chorionic gonadotropin \[β-hCG\]) pregnancy test at screening and within 72 hours before the first dose of study treatment, and agree to further pregnancy tests, ii. Practice at least 1 highly effective method of contraception; if oral contraceptives are used, a barrier method of contraception must also be used.
e. If a patient's partner is of childbearing potential, the participant must use a condom and partner of the participant must also be practicing a highly effective method of contraception. A vasectomized patient must still use a condom, but the partner is not required to use contraception.
8. Resolution of prior-therapy-related AEs (including immune-related AEs but excluding alopecia) to ≤ Grade 1 per CTCAE v 5.0, and no treatment for these AEs for at least 2 weeks prior to the time of enrollment. Alopecia, sensory neuropathy Grade ≤ 2, or other Grade ≤ 2 AEs not constituting a safety risk based on investigator's judgment are acceptable.
9. Adequate organ function as indicated by laboratory values.
10. Submit tissue and blood specimens.
<!-- -->
1. Cohort 1:
1. All patients should submit tumor tissue/block collected from fresh biopsy or have available archival formalin-fixed, paraffin-embedded tumor tissue specimen. The archival tissue must be:
* collected after progression from most recent prior systemic anti-cancer treatment, OR
* If an archival tissue collected after progression to the most recent systemic anti-cancer treatment is not available, tissue samples from previous lines of treatment are acceptable.
For fresh biopsied sample, core needle biopsy is permitted. Samples from fine-needle aspiration (FNA) is not acceptable unless the result of MET exon 14 skipping from local testing is available.
2. All patients must submit blood samples.
2. Cohort 2:
1. All patients should submit either fresh or archival tumor slides/block collected after progression from 1st line 3rd generation EGFR TKI. The archival tissue can be permitted ONLY IF it is collected after progression from 1st line 3rd generation EGFR TKI.
2. All patients should submit blood samples. 11. Able and willing to comply with the protocol and the restrictions and assessments therein.
2. Eastern Cooperative Oncology Group (ECOG) performance status (PS), 0 or 1.
3. Have a life expectancy of at least 3 months.
4. Diagnosis:
1. must have histologically or cytologically confirmed NSCLC, advanced, recurrent, or metastatic,
2. For Cohort 1: MET exon 14 skipping suspected by local or central biomarker assessment. \[local testing is accepted for eligibility; all patients will have confirmation by central laboratory, but this result is not necessary for eligibility; local molecular pathology result will suffice\]. This testing can be from archival or fresh tissue sample and/or blood specimen; any sample, any test positive subjects are eligible.
3. For Cohort 2:
* Non-squamous histology (confirmed by histology or cytology)
* EGFR mutation-positive including exon 19 deletions or exon 21 L858R as detected by an FDA-approved or other validated test in a CLIA certified laboratory (sites in the US) or an accredited local laboratory (sites outside of the US) in accordance with site standard of care. (Note: A copy of the test report documenting the EGFR mutation must be included in the participant records and it must be reviewed by the Medical monitor.)
* Radiological documentation of disease progression while on continuous treatment with the 1st line 3rd generation EGFR-TKI
* Prior objective clinical benefit defined by either partial or complete radiological response, or durable SD (SD should last \> 6 months) from the 1st line 3rd generation EGFR-TKI
* Interval between documentation of radiological progression of disease on the 1st line 3rd generation EGFR TKI and first dose of study drug should be ≤ 60 days
* MET amplification or overexpression from tumor sample collected following progression on 1st line 3rd generation EGFR-TKI • Amplification GCN ≥ 10 indicated by FISH (confirmed centrally, slides or image from local laboratory will be confirmed by the central pathologist) or NGS (confirmed either centrally or locally) • Overexpression indicated by IHC90+ (i.e. 3+ staining in ≥ 90% tumor cells by central test, if local IHC results are available, image from local laboratory will be confirmed by central pathologist. Despite the image submission, tissue unstained slides should be sent to central laboratory for confirmation of MET amplification or overexpression.)
5. Treatment experience
1. Cohort 1: Anti-tumor treatment naïve subject upon refusal to receive 1st line standard of care, or not tolerated to 1st line standard of care, or progressed after standard of care with no greater than 2 prior treatment regimens (neoadjuvant, adjuvant, and maintenance therapies do not qualify as separate treatment regimens).
2. Cohort 2: Progressed on prior the 1st line 3rd generation EGFR-TKI for the treatment of advanced/metastatic NSCLC
6. At least one measurable lesion per response evaluation criteria in solid tumors (RECIST) 1.1
7. While on study treatment and for 6 months after the last dose of study treatment, a patient must:
1. Not breast feed or be pregnant.
2. Not donate gametes (ie, eggs or sperm) or freeze for future use for the purpose of assisted reproduction.
3. Wear an external condom when engaging in any activity that allows for passage of ejaculate to another person.
4. If of childbearing potential
i. Have a negative highly sensitive (eg, beta-human chorionic gonadotropin \[β-hCG\]) pregnancy test at screening and within 72 hours before the first dose of study treatment, and agree to further pregnancy tests, ii. Practice at least 1 highly effective method of contraception; if oral contraceptives are used, a barrier method of contraception must also be used.
e. If a patient's partner is of childbearing potential, the participant must use a condom and partner of the participant must also be practicing a highly effective method of contraception. A vasectomized patient must still use a condom, but the partner is not required to use contraception.
8. Resolution of prior-therapy-related AEs (including immune-related AEs but excluding alopecia) to ≤ Grade 1 per CTCAE v 5.0, and no treatment for these AEs for at least 2 weeks prior to the time of enrollment. Alopecia, sensory neuropathy Grade ≤ 2, or other Grade ≤ 2 AEs not constituting a safety risk based on investigator's judgment are acceptable.
9. Adequate organ function as indicated by laboratory values.
10. Submit tissue and blood specimens.
<!-- -->
1. Cohort 1:
1. All patients should submit tumor tissue/block collected from fresh biopsy or have available archival formalin-fixed, paraffin-embedded tumor tissue specimen. The archival tissue must be:
* collected after progression from most recent prior systemic anti-cancer treatment, OR
* If an archival tissue collected after progression to the most recent systemic anti-cancer treatment is not available, tissue samples from previous lines of treatment are acceptable.
For fresh biopsied sample, core needle biopsy is permitted. Samples from fine-needle aspiration (FNA) is not acceptable unless the result of MET exon 14 skipping from local testing is available.
2. All patients must submit blood samples.
2. Cohort 2:
1. All patients should submit either fresh or archival tumor slides/block collected after progression from 1st line 3rd generation EGFR TKI. The archival tissue can be permitted ONLY IF it is collected after progression from 1st line 3rd generation EGFR TKI.
2. All patients should submit blood samples. 11. Able and willing to comply with the protocol and the restrictions and assessments therein.
Exclusion Criteria
1. Previous severe hypersensitivity reaction to any component of study drug(s).
2. Prior therapy
a. Previous treatment with c-MET inhibitors or hepatocyte growth factor (HGF)-targeting therapy.
b. For Cohort 2, prior chemotherapy for advanced, recurrent, or metastatic setting.
3. Genetic analysis results:
1. Cohort 1: Existing genetic data from the patient's tumor tissue showing known molecular alterations which would make them eligible for targeted therapies (e.g., EGFR mutations, ALK rearrangements, KRAS mutation, ROS1 translocation, BRAF mutation, RET alteration, and NTRK fusion, etc.).
2. Cohort 2: Patients with known molecular alterations that can't benefit from study medication (e.g., EGFR mutation known to be associated with the resistance to 3rd generation EGFR TKIs, such as C797X or insertion 20, ALK rearrangements, KRAS mutation, ROS1 translocation, BRAF mutation, RET alteration, and NTRK fusion, etc.).
4. Chronic inflammatory liver condition. History or clinical evidence of any significant liver or biliary pathology including cirrhosis, infectious disease, inflammatory conditions, steatosis, or cholangitis (including ascending cholangitis, primary sclerosing cholangitis, obstruction, perforation, fistula of biliary tract, spasm of sphincter of Oddi, biliary cyst or biliary atresia).
5. Past medical history of Interstitial Lung Disease (ILD)/pneumonitis, drug-induced or radiation ILD/pneumonitis that required steroid treatment or other immune suppressive agents, or evidence of current symptomatic interstitial lung disease or unexplained pulmonary symptoms indicative of ILD such dyspnea, cough, or fever.
6. Impairment of Gastrointestinal (GI) function or GI disease that may significantly alter the absorption of study drugs (e.g., ulcerative diseases, uncontrolled nausea, uncontrolled vomiting, uncontrolled diarrhea, or malabsorption syndrome)
7. Prior organ or stem cell transplant.
8. Known active infection with human immunodeficiency virus (HIV), human T-cell leukemia virus, type (HTLV-1), hepatitis B virus (HBV), or hepatitis C virus (HCV), unless the patients fall into below categories (patients fall into one of the a, b, c category are eligible to participate)
1. HIV
✓ CD4+ cells ≥ 350 cells/µL
✓ No history of AIDS
✓ No history of opportunistic infection in the past 12 months
2. HCV
✓ Undetectable viral load (Participants positive for hepatitis C antibody are eligible only if polymerase chain reaction is negative for hepatitis C RNA)
3. HBV ✓ Concurrent HBV treatment and undetectable viral load (Participants with a past or resolved hepatitis B infection defined as the presence of hepatitis B core antibody \[anti-HBc\] and absence of hepatitis B surface antigen are eligible)
9. Symptomatic ascites or pleural effusion, unless clinically stable for at least two weeks following treatment for these conditions (including therapeutic thoraco- or paracentesis).
10. Known active central nervous system (CNS) primary tumor or metastases and/or carcinomatous meningitis. Patients with previously treated brain metastases may participate provided they are clinically stable for at least 4 weeks prior to first dose of study medication(s), have no evidence of new or enlarging brain metastases and are off steroids for at least 15 days prior to first dose of study medication(s).
11. Presence or history of a malignant disease other than disease to be treated in current protocol that has been diagnosed and/or required therapy within the past 3 years. Exceptions to this exclusion include the following: completely resected basal cell and squamous cell skin cancers, indolent malignancies that currently do not require treatment, and completely resected carcinoma in situ of any type.
12. Active infection requiring therapy. However, subject with minor infections requiring oral antibiotics, (e.g., urinary tract infection, Upper respiratory tract infection, etc.) could be eligible based on investigator's judgement.
13. Use of systemic corticosteroids \> 10 mg/day prednisone or equivalent within 30 days or other immunosuppressive drugs within 30 days prior to first drug administration.
14. Patients receiving treatment with medications that meet one of the following criteria and that cannot be discontinued specified period prior to the start of treatment with study drug and for the duration of the study.
For Vabametkib (Wash-out: 1 week)
• Strong and moderate inhibitors/inducers of P-glycoprotein
• Strong and moderate inhibitors/inducers of CYP3A4
• Proton pump inhibitors (PPI)
• Potassium-competitive acid blockers For Lazertinib
* Strong and moderate CYP3A4 inducers
* Medications possibly prolong QT interval or induce Torsades de Pointes
15. Has received or will receive a live vaccine within 30 days prior to the first administration of study medication. Seasonal flu vaccine that does not contain live vaccine are permitted.
16. Received an investigational product (except for EGFR TKI in Cohort 2) or treated with an investigational device within 30 days prior to first study drug administration.
17. Has been receiving: radiotherapy, chemotherapy, or molecularly-targeted agents or tyrosine kinase inhibitors (except for EGFR TKI in Cohort 2) within 2 weeks (4 weeks in case of thoracic radiotherapy to lung fields) or 5 half-lives (whichever is longer) of the start of study treatment; immunotherapy/monoclonal antibodies within 3 weeks of the start of study treatment; nitrosoureas, antibody-drug conjugates, or radioactive isotopes within 6 weeks of the start of study treatment; 7-day washout is permitted for palliative radiation (i.e. limited field, ≤ 14-day course of radiotherapy) to non-CNS lesions.
18. History or clinical evidence of any surgical or medical condition which the investigator judges as likely to interfere with the results of the study or pose an additional risk in participating e.g., rapidly progressive or uncontrolled disease involving a major organ system-vascular, ophthalmologic, cardiac (clinically important abnormalities in rhythm, conduction or morphology of resting ECG, uncontrolled hypertension, uncontrolled symptomatic heart failure), pulmonary, gastrointestinal, gynecologic, hematologic, neurologic, neoplastic, renal, endocrine, autoimmune or an immunodeficiency, or clinically significant active psychiatric or abuse disorders.
19. Is a regular user (including "recreational use") of any illicit drugs or had a recent history (within the last year) of substance abuse (including alcohol).
20. Patients with a corrected QT interval (using Fridericia's correction formula) (QTcF) of \> 470 msec.
21. Any factors that increase the risk of QTc prolongation or risk of arrhythmic events such as, hypokalemia, congenital long QT syndrome, family history of long QT syndrome, or unexplained sudden death under 40 years of age in first degree relatives or any concomitant medications known to prolong QT interval or induce Torsades de Pointes.
22. Congestive heart failure (CHF), defined as New York Heart Association (NYHA) class III-IV or hospitalization for CHF (any NYHA class), within 6 months of randomization.
23. An active or past medical history of pericarditis, pericardial effusion that is clinically unstable, or myocarditis. Pericardial effusion considered due to the disease under study is permitted if clinically stable at Screening.
24. (for Cohort 2) Baseline LVEF either \<50% or below the lower limit of normal (LLN) per institutional guidelines, as assessed by screening echocardiogram or MUGA scan.
25. (for Cohort 2) Patients who have been receiving medications with potential for QT interval prolongation will be eligible only when the wash out period was finished.
2. Prior therapy
a. Previous treatment with c-MET inhibitors or hepatocyte growth factor (HGF)-targeting therapy.
b. For Cohort 2, prior chemotherapy for advanced, recurrent, or metastatic setting.
3. Genetic analysis results:
1. Cohort 1: Existing genetic data from the patient's tumor tissue showing known molecular alterations which would make them eligible for targeted therapies (e.g., EGFR mutations, ALK rearrangements, KRAS mutation, ROS1 translocation, BRAF mutation, RET alteration, and NTRK fusion, etc.).
2. Cohort 2: Patients with known molecular alterations that can't benefit from study medication (e.g., EGFR mutation known to be associated with the resistance to 3rd generation EGFR TKIs, such as C797X or insertion 20, ALK rearrangements, KRAS mutation, ROS1 translocation, BRAF mutation, RET alteration, and NTRK fusion, etc.).
4. Chronic inflammatory liver condition. History or clinical evidence of any significant liver or biliary pathology including cirrhosis, infectious disease, inflammatory conditions, steatosis, or cholangitis (including ascending cholangitis, primary sclerosing cholangitis, obstruction, perforation, fistula of biliary tract, spasm of sphincter of Oddi, biliary cyst or biliary atresia).
5. Past medical history of Interstitial Lung Disease (ILD)/pneumonitis, drug-induced or radiation ILD/pneumonitis that required steroid treatment or other immune suppressive agents, or evidence of current symptomatic interstitial lung disease or unexplained pulmonary symptoms indicative of ILD such dyspnea, cough, or fever.
6. Impairment of Gastrointestinal (GI) function or GI disease that may significantly alter the absorption of study drugs (e.g., ulcerative diseases, uncontrolled nausea, uncontrolled vomiting, uncontrolled diarrhea, or malabsorption syndrome)
7. Prior organ or stem cell transplant.
8. Known active infection with human immunodeficiency virus (HIV), human T-cell leukemia virus, type (HTLV-1), hepatitis B virus (HBV), or hepatitis C virus (HCV), unless the patients fall into below categories (patients fall into one of the a, b, c category are eligible to participate)
1. HIV
✓ CD4+ cells ≥ 350 cells/µL
✓ No history of AIDS
✓ No history of opportunistic infection in the past 12 months
2. HCV
✓ Undetectable viral load (Participants positive for hepatitis C antibody are eligible only if polymerase chain reaction is negative for hepatitis C RNA)
3. HBV ✓ Concurrent HBV treatment and undetectable viral load (Participants with a past or resolved hepatitis B infection defined as the presence of hepatitis B core antibody \[anti-HBc\] and absence of hepatitis B surface antigen are eligible)
9. Symptomatic ascites or pleural effusion, unless clinically stable for at least two weeks following treatment for these conditions (including therapeutic thoraco- or paracentesis).
10. Known active central nervous system (CNS) primary tumor or metastases and/or carcinomatous meningitis. Patients with previously treated brain metastases may participate provided they are clinically stable for at least 4 weeks prior to first dose of study medication(s), have no evidence of new or enlarging brain metastases and are off steroids for at least 15 days prior to first dose of study medication(s).
11. Presence or history of a malignant disease other than disease to be treated in current protocol that has been diagnosed and/or required therapy within the past 3 years. Exceptions to this exclusion include the following: completely resected basal cell and squamous cell skin cancers, indolent malignancies that currently do not require treatment, and completely resected carcinoma in situ of any type.
12. Active infection requiring therapy. However, subject with minor infections requiring oral antibiotics, (e.g., urinary tract infection, Upper respiratory tract infection, etc.) could be eligible based on investigator's judgement.
13. Use of systemic corticosteroids \> 10 mg/day prednisone or equivalent within 30 days or other immunosuppressive drugs within 30 days prior to first drug administration.
14. Patients receiving treatment with medications that meet one of the following criteria and that cannot be discontinued specified period prior to the start of treatment with study drug and for the duration of the study.
For Vabametkib (Wash-out: 1 week)
• Strong and moderate inhibitors/inducers of P-glycoprotein
• Strong and moderate inhibitors/inducers of CYP3A4
• Proton pump inhibitors (PPI)
• Potassium-competitive acid blockers For Lazertinib
* Strong and moderate CYP3A4 inducers
* Medications possibly prolong QT interval or induce Torsades de Pointes
15. Has received or will receive a live vaccine within 30 days prior to the first administration of study medication. Seasonal flu vaccine that does not contain live vaccine are permitted.
16. Received an investigational product (except for EGFR TKI in Cohort 2) or treated with an investigational device within 30 days prior to first study drug administration.
17. Has been receiving: radiotherapy, chemotherapy, or molecularly-targeted agents or tyrosine kinase inhibitors (except for EGFR TKI in Cohort 2) within 2 weeks (4 weeks in case of thoracic radiotherapy to lung fields) or 5 half-lives (whichever is longer) of the start of study treatment; immunotherapy/monoclonal antibodies within 3 weeks of the start of study treatment; nitrosoureas, antibody-drug conjugates, or radioactive isotopes within 6 weeks of the start of study treatment; 7-day washout is permitted for palliative radiation (i.e. limited field, ≤ 14-day course of radiotherapy) to non-CNS lesions.
18. History or clinical evidence of any surgical or medical condition which the investigator judges as likely to interfere with the results of the study or pose an additional risk in participating e.g., rapidly progressive or uncontrolled disease involving a major organ system-vascular, ophthalmologic, cardiac (clinically important abnormalities in rhythm, conduction or morphology of resting ECG, uncontrolled hypertension, uncontrolled symptomatic heart failure), pulmonary, gastrointestinal, gynecologic, hematologic, neurologic, neoplastic, renal, endocrine, autoimmune or an immunodeficiency, or clinically significant active psychiatric or abuse disorders.
19. Is a regular user (including "recreational use") of any illicit drugs or had a recent history (within the last year) of substance abuse (including alcohol).
20. Patients with a corrected QT interval (using Fridericia's correction formula) (QTcF) of \> 470 msec.
21. Any factors that increase the risk of QTc prolongation or risk of arrhythmic events such as, hypokalemia, congenital long QT syndrome, family history of long QT syndrome, or unexplained sudden death under 40 years of age in first degree relatives or any concomitant medications known to prolong QT interval or induce Torsades de Pointes.
22. Congestive heart failure (CHF), defined as New York Heart Association (NYHA) class III-IV or hospitalization for CHF (any NYHA class), within 6 months of randomization.
23. An active or past medical history of pericarditis, pericardial effusion that is clinically unstable, or myocarditis. Pericardial effusion considered due to the disease under study is permitted if clinically stable at Screening.
24. (for Cohort 2) Baseline LVEF either \<50% or below the lower limit of normal (LLN) per institutional guidelines, as assessed by screening echocardiogram or MUGA scan.
25. (for Cohort 2) Patients who have been receiving medications with potential for QT interval prolongation will be eligible only when the wash out period was finished.
Minimum Eligible Age
18 Years
Eligible Sex
ALL
Accepts Healthy Volunteers
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Abion Inc
INDUSTRY
Sponsor Role
lead
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Responsibility Role
SPONSOR
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Cancer Care of North Florida, PA (Lake City Cancer Care, LLC) - Medical Oncology
Lake City, Florida, United States
Site Status
RECRUITING
Mid Florida Center
Orange City, Florida, United States
Site Status
RECRUITING
The Henry Ford Cancer Institute
Detroit, Michigan, United States
Site Status
NOT_YET_RECRUITING
The University of Texas MD Anderson Cancer Center
Houston, Texas, United States
Site Status
RECRUITING
National Cancer Center
Goyang-si, Gyeonggi-do, South Korea
Site Status
RECRUITING
Ajou University Hospital
Suwon, Gyeonggi-do, South Korea
Site Status
RECRUITING
Boramae Medical Center
Dongjak, Seoul, South Korea
Site Status
RECRUITING
Korea University Anam Hospital
Seoul, Seoul, South Korea
Site Status
RECRUITING
Severance Hospital
Sinchon-dong, Seoul, South Korea
Site Status
RECRUITING
Chungbuk National University Hospital
Cheongju-si, , South Korea
Site Status
RECRUITING
Gachon University Gil Medical Center
Incheon, , South Korea
Site Status
RECRUITING
Gyeongsang National University Hospital
Jinju, , South Korea
Site Status
RECRUITING
Seoul National University Bundang Hospital
Seongnam-si, , South Korea
Site Status
RECRUITING
Kangbuk Samsung Hospital
Seoul, , South Korea
Site Status
RECRUITING
Asan Medical Center
Seoul, , South Korea
Site Status
RECRUITING
Samsung Medical Center
Seoul, , South Korea
Site Status
RECRUITING
The Catholic University of Korea, Seoul St Mary's Hospitals
Seoul, , South Korea
Site Status
RECRUITING
The Catholic University of Korea St Vincents Hospital
Suwon, , South Korea
Site Status
RECRUITING
China Medical University Hospital
Taichung, , Taiwan
Site Status
RECRUITING
National Cheng Kung University Hospital
Tainan City, , Taiwan
Site Status
RECRUITING
Chi Mei Hospital, Liouying
Tainan City, , Taiwan
Site Status
RECRUITING
National Taiwan University Cancer Center (NTUCC)
Taipei, , Taiwan
Site Status
RECRUITING
National Taiwan University Hospital
Taipei, , Taiwan
Site Status
RECRUITING
Taipei Veterans General Hospital
Taipei, , Taiwan
Site Status
RECRUITING
Countries
Review the countries where the study has at least one active or historical site.
United States
South Korea
Taiwan
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
ABN401-003
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.
A Study of ABM-1310 in Patients With BRAF V600-Mutant Advanced Solid Tumors
NCT05501912
TERMINATED
PHASE1
Safety Study of MM-121 in Combination With Multiple Anticancer Therapies in Patients With Advanced Solid Tumors
NCT01447225
COMPLETED
PHASE1
Absorption, Metabolism, Excretion and Pharmacokinetics of a Single Dose [14C]AZD2014 Followed by a Multiple Dose Phase
NCT02640755
COMPLETED
PHASE1
A Study to Assess Safety and Efficacy of SOT201 in Patients With Advanced/Metastatic Cancer
NCT06163391
RECRUITING
PHASE1
Dose Escalation Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of QBS10072S
NCT04430842
COMPLETED
PHASE1
Study to Explore the Safety, Tolerability, and Pharmacokinetics of AMG 305 in Subjects With Advanced Solid Tumors
NCT05800964
ACTIVE_NOT_RECRUITING
PHASE1
Study of MHB088C in Participants With Advanced or Metastatic Solid Tumors
NCT05652855
NOT_YET_RECRUITING
PHASE1/PHASE2
Safety and Tolerability of ABM-1310 in Patients With Advanced Solid Tumors
NCT04190628
TERMINATED
PHASE1
A Study of Mipasetamab Uzoptirine (ADCT-601) in Participants With Solid Tumors
NCT05389462
TERMINATED
PHASE1
A Study to Assess Safety, Tolerability, and Pharmacokinetics of ABSK061 in Patients With Advanced Solid Tumors
NCT05244551
RECRUITING
PHASE1
A Study to Investigate ANS014004 in Participants With Locally Advanced or Metastatic Solid Tumors
NCT06307795
RECRUITING
PHASE1
AMG 193 Alone or in Combination With Other Therapies in Subjects With Advanced Thoracic Tumors With Homozygous MTAP-deletion (Master Protocol) (MTAPESTRY 104).
NCT06333951
RECRUITING
PHASE1
A Study of HB002.1T Plus Chemotherapy in Subjects With Solid Tumor
NCT04802980
UNKNOWN
PHASE1
A Study to Assess the Safety, Tolerability, and Pharmacokinetics of ABSK-021 in Patients With Advanced Solid Tumor
NCT04192344
RECRUITING
PHASE1
A Early Study of ABSK131 in Patients With Advanced/Metastatic Solid Tumors
NCT07288957
RECRUITING
PHASE1
A Study of ES014 in Patients With Locally Advanced or Metastatic Solid Tumours
NCT05717348
ACTIVE_NOT_RECRUITING
PHASE1
SHR-1701 in Subjects With Metastatic or Locally Advanced Solid Tumors
NCT03774979
UNKNOWN
PHASE1
A Study of MHB042C in Patients With Advanced Solid Tumors
NCT07192107
RECRUITING
PHASE1/PHASE2
A Phase 1-2 Study of ST101 in Patients With Advanced Solid Tumors
NCT04478279
ACTIVE_NOT_RECRUITING
PHASE1/PHASE2
Safety and Effectiveness of ABM-168 in Adults with Advanced Solid Tumors.
NCT05831995
TERMINATED
PHASE1
A Study to Evaluate the Safety, Pharmacokinetics, and Antitumor Activity of AK127 in Combination With AK104 in Advanced and Metastatic Solid Tumours
NCT05021120
COMPLETED
EARLY_PHASE1
A Study of MHB048C in Patients With Advanced Solid Tumors
NCT07192120
RECRUITING
PHASE1/PHASE2
MSX-122 Administered Orally in Patients With Refractory Metastatic or Locally Advanced Solid Tumors
NCT00591682
SUSPENDED
PHASE1
Study of the Safety, Pharmacokinetics, and Antitumor Activity of AK105 in Subjects With Advanced Solid Tumors
NCT03352531
COMPLETED
PHASE1
Safety and Efficacy of HCB101 in Combination With Multiple Agents in Patients With Advanced Solid Tumors
NCT06771622
ACTIVE_NOT_RECRUITING
PHASE1/PHASE2